DMYD-B:STO
Diamyd Medical AB
SEK 0.94
arrow_downward
-0.21%(-0.0020) 1D
10-р сарын 8, 11:08:59 (GMT+2) · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
SEK 0.95
High
SEK 0.99
Low
SEK 0.93
Mkt. cap
141.57 сая
Avg. vol.
732.10 мян
Volume
118.11 мян
52-wk high
SEK 17.88
52-wk low
SEK 0.90
EPS
-SEK 1.98
Shares outstanding
134.00 сая
No. of employees
44
Open
SEK 0.95
High
SEK 0.99
Low
SEK 0.93
Mkt. cap
141.57 сая
Avg. vol.
732.10 мян
Volume
118.11 мян
52-wk high
SEK 17.88
52-wk low
SEK 0.90
EPS
-SEK 1.98
Shares outstanding
134.00 сая
No. of employees
44
News stories
From web sources and news partners
Bloomberg Government News
·
17 минутын өмнө
Nasdaq-Listed Lobbying Firm Launches Capitol Hill Oversight Unit
www.marketscreener.com
·
18 минутын өмнө
Kyivstar to Report 3Q26 Results on November 6, 2026
Yahoo Finance
·
1 цагийн өмнө
Prediction: The S&P 500 Will Hit 10,000 in 2027
Bloomberg.com
·
3 цагийн өмнө
AI Bubble Risks Worst S&P 500 Crash Since 2008, Strategist Says
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB